TABLE 1.
The clinical and neuroimaging characteristics of patients with CSVD
| CSVD patients (n = 113) | Controls (n = 83) | p | |
|---|---|---|---|
| Age (years) | 56.01 ± 10.62 | 53.65 ± 9.27 | 0.202 |
| Sex (male/female) | 92/21 | 69/14 | 0.757 |
| Current smoking | 74 (65.5) | 45 (42.2) | 0.110 |
| Excessive drinking | 47 (41.6) | 26 (31.3) | 0.142 |
| Hypertension | 68 (60.2) | 33 (39.8) | 0.005* |
| Diabetes | 27 (23.9) | 11 (13.3) | 0.063 |
| Hyperlipidemia | 67 (59.3) | 34 (41.0) | 0.011* |
| Antihypertensive treatment | 25 (22.1) | ||
| Statin | 31 (27.4) | ||
| Antiplatelet treatment | 42 (37.2) | ||
| Antidiabetic treatment | 14 (12.4) | ||
| FBG (mmol/L) | 5.22 (4.81–6.26) | ||
| Triglyceride (mmol/L) | 1.57 (1.12–2.91) | ||
| Total cholesterol (mmol/L) | 4.87 ± 1.00 | ||
| LDL‐C (mmol/L) | 2.89 ± 0.66 | ||
| Urid acid (mmol/L) | 335.0 (283.0–389.0) | ||
| Lacunes | 78 (69.0) | ||
| PWMH | 64 (56.6) | ||
| DWMH | 44 (38.9) | ||
| PVS | 81 (71.7) | ||
| Lobar CMBs | 17 (15.0) | ||
| Deep CMBs | 27 (23.9) | ||
| Total CSVD burden score | |||
| 0 | 23 (20.4) | ||
| 1 | 37 (32.7) | ||
| 2 | 31 (27.4) | ||
| 3 | 10 (8.8) | ||
| 4 | 12 (10.6) | ||
Abbreviations: CMBs, cerebral microbleeds; CSVD, cerebral small vessel disease; DWMH, deep white matter hyperintensities; FBG, fasting blood glucose; LDL‐C, low‐density lipoprotein cholesterol; PVS, perivascular spaces; PWMH, periventricular white matter hyperintensities.
∗
p < 0.05 for comparison with controls.